173 related articles for article (PubMed ID: 15741301)
1. Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer.
Osanai T; Takagi Y; Toriya Y; Nakagawa T; Aruga T; Iida S; Uetake H; Sugihara K
Jpn J Clin Oncol; 2005 Mar; 35(3):121-5. PubMed ID: 15741301
[TBL] [Abstract][Full Text] [Related]
2. O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma.
Cayre A; Penault-Llorca F; De Latour M; Rolhion C; Feillel V; Ferrière JP; Kwiatkowski F; Finat-Duclos F; Verrelle P
Int J Oncol; 2002 Nov; 21(5):1125-31. PubMed ID: 12370764
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations.
Kim JI; Suh JT; Choi KU; Kang HJ; Shin DH; Lee IS; Moon TY; Kim WT
Hum Pathol; 2009 Jul; 40(7):934-41. PubMed ID: 19356788
[TBL] [Abstract][Full Text] [Related]
6. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
7. [The expression of O6-methylguanine DNA methyltransferase and p53 in non-small cell lung cancer and the association with the prognosis].
Liu Y; Wang J; Zhang H; Fu XM; Wang HQ
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun; 33(6):427-31. PubMed ID: 20979814
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis.
Nakamura Y; Yasuoka H; Tsujimoto M; Yoshidome K; Nakahara M; Nakao K; Nakamura M; Kakudo K
Clin Cancer Res; 2006 Feb; 12(4):1201-7. PubMed ID: 16489074
[TBL] [Abstract][Full Text] [Related]
9. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival.
Hanzal E; Gitsch G; Kohlberger P; Dadak C; Miechowiecka N; Breitenecker G
Anticancer Res; 1992; 12(6B):2325-9. PubMed ID: 1295480
[TBL] [Abstract][Full Text] [Related]
11. Alteration of O6-methylguanine-DNA methyltransferase in colorectal neoplasms in sporadic and familial adenomatous polyposis patients.
Kim SH; Bae SI; Lee HS; Kim WH
Mol Carcinog; 2003 May; 37(1):32-8. PubMed ID: 12720298
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
14. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes.
Arun B; Kilic G; Yen C; Foster B; Yardley D; Gaynor R; Ashfaq R
Cancer; 2003 Dec; 98(12):2554-9. PubMed ID: 14669273
[TBL] [Abstract][Full Text] [Related]
15. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546
[TBL] [Abstract][Full Text] [Related]
16. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.
Woo SU; Bae JW; Kim CH; Lee JB; Koo BW
Ann Surg Oncol; 2008 Jan; 15(1):281-5. PubMed ID: 17763975
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer.
Midulla C; De Iorio P; Nagar C; Pisani T; Cenci M; Valli C; Nofroni I; Vecchione A
Anticancer Res; 1999; 19(5B):4033-7. PubMed ID: 10628350
[TBL] [Abstract][Full Text] [Related]
18. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.
Linder N; Lundin J; Isola J; Lundin M; Raivio KO; Joensuu H
Clin Cancer Res; 2005 Jun; 11(12):4372-81. PubMed ID: 15958620
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma.
O'Hanlon DM; Kiely M; MacConmara M; Al-Azzawi R; Connolly Y; Jeffers M; Keane FB
Eur J Surg Oncol; 2002 Mar; 28(2):103-7. PubMed ID: 11884043
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
